Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology : RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. European Journal of Haematology 2010; 85 (6):484–491.
Jack Ishak, Filipe RodriguesVolume:
87
Year:
2011
Language:
english
Pages:
1
DOI:
10.1111/j.1600-0609.2011.01624.x
File:
PDF, 49 KB
english, 2011